Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Grows By 46.3%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 986,700 shares, a growth of 46.3% from the January 31st total of 674,300 shares. Based on an average daily trading volume, of 295,700 shares, the days-to-cover ratio is presently 3.3 days. Approximately 4.7% of the shares of the stock are sold short.

Insider Activity

In related news, Director Stan Smith purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of $1.87 per share, with a total value of $46,750.00. Following the acquisition, the director now owns 1,130,060 shares of the company’s stock, valued at $2,113,212.20. This trade represents a 2.26 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 36.98% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors have recently added to or reduced their stakes in MAIA. XTX Topco Ltd acquired a new position in shares of MAIA Biotechnology in the 3rd quarter worth approximately $31,000. Geode Capital Management LLC lifted its position in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after purchasing an additional 35,821 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of MAIA Biotechnology in the 4th quarter worth approximately $77,000. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Stock Down 2.9 %

MAIA opened at $1.65 on Wednesday. MAIA Biotechnology has a fifty-two week low of $1.27 and a fifty-two week high of $5.99. The company has a market cap of $43.16 million, a price-to-earnings ratio of -1.20 and a beta of 0.20. The stock’s 50 day simple moving average is $1.97.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.